Business Context and Reporting Period
Company: Jackson Acquisition Company II (JACS)
Reporting Period: Fiscal year ended December 31, 2025
Business Type: Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands.
Objective: To effect a merger or business combination with one or more businesses, primarily focusing on healthcare services, healthcare technology, or the broader healthcare industry.
Status: Pre-business combination. The Company has no operating revenues and is currently identifying potential targets. It must complete an initial business combination by December 11, 2026, or face mandatory liquidation.
Key Financial Metrics
| Metric | Year Ended Dec 31, 2025 | Period from Inception (Sep 11, 2024) to Dec 31, 2024 |
|---|---|---|
| Net Income | $9,115,597 | $381,082 |
| Interest Income (Trust Account) | $9,684,710 | $558,478 |
| General & Administrative Expenses | $569,113 | $177,396 |
| Trust Account Balance | $242,543,188 | $232,858,478 |
| Cash (Outside Trust) | $521,776 | $949,366 |
| Net Cash Used in Operating Activities | ($427,590) | ($302,833) |
| Redemption Value per Public Share | $10.55 | $10.12 |
Debt and Liquidity: As of December 31, 2025, there were no outstanding Working Capital Loans. A related-party promissory note of $198,024 remains outstanding. The Company holds $521,776 in cash outside the Trust Account for working capital needs.
Material Changes vs. Prior Period
- Trust Account Growth: The Trust Account balance increased by approximately $9.68 million, driven entirely by interest earned on marketable securities (U.S. Treasury obligations and money market funds).
- Operating Expenses: General and administrative costs increased to $569,113 for the full year 2025 compared to $177,396 for the partial period in 2024, reflecting ongoing operational costs as a public company.
- Net Income: Net income for 2025 was significantly higher than the inception-to-date 2024 figure, primarily due to the full year of interest accrual in the Trust Account.
- Cash Position: Cash held outside the Trust Account decreased from $949,366 to $521,776 due to operating cash outflows.
Guidance, Outlook, Risks, and Contingencies
Outlook and Timeline: The Company has until December 11, 2026 (24 months from IPO) to consummate a business combination. If unsuccessful, the Company will liquidate and distribute Trust Account funds to public shareholders.
Going Concern: Management has identified substantial doubt about the Company's ability to continue as a going concern due to the mandatory liquidation date and the expectation of significant future costs. Management plans to address this through debt or equity financing, though there is no assurance of success.
Key Risks:
- Liquidation Risk: Failure to complete a business combination by the deadline results in dissolution.
- Redemption Risk: Significant redemptions by public shareholders could reduce the cash available for a transaction, potentially requiring additional financing (PIPE or debt).
- Conflicts of Interest: Directors and officers have fiduciary duties to other entities (e.g., Jackson Healthcare, Jackson Investment Group) and may prioritize those opportunities over the SPAC.
- Market Conditions: Geopolitical instability and macroeconomic conditions could impact the ability to find a target or secure financing.
Contingencies: The Sponsor has agreed to indemnify the Trust Account against certain third-party claims to ensure at least $10.10 per share remains available for redemption, though the Sponsor's ability to satisfy this obligation is not independently verified.
Investor Verification Checklist
- Trust Account Yield: Verify the current interest rate environment and its impact on the redemption value per share ($10.55 as of Dec 31, 2025).
- Extension Provisions: Review the specific terms required to extend the combination deadline beyond December 11, 2026, and the associated costs.
- Related Party Transactions: Confirm the status of the $198,024 promissory note and the $127,000 owed to the Sponsor for administrative services.
- Target Pipeline: Assess management's progress in identifying a target, noting that no definitive agreement has been signed.
- Redemption Thresholds: Understand the 15% limitation on redemptions for "Excess Shares" if a shareholder vote is required.